X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
FTX-1821 (losmapimod) is a small molecule, which is act as selective p38alpha/beta mitogen activated protein kinase (MAPK) inhibitor, which is investigated for the treatment of facioscapulohumeral muscular dystrophy.
Lead Product(s): Losmapimod
Therapeutic Area: Musculoskeletal Product Name: FTX-1821
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2023
Details:
Fulcrum gains worldwide license to intellectual property arising from CAMP4’s DBA program, including the rights for discovery, development, and commercialization of novel therapeutic agents against an undisclosed target for the potential treatment of Diamond-Blackfan Anemia.
Lead Product(s): Undisclosed
Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Recipient: CAMP4 Therapeutics
Deal Size: $70.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 10, 2023
Details:
The collaboration aims for the development of FTX-1821 (losmapimod), an investigational small molecule inhibitor of p38α/β Mitogen Activated Protein Kinase (MAPK), for the treatment of facioscapulohumeral muscular dystrophy (FSHD).
Lead Product(s): Losmapimod
Therapeutic Area: Musculoskeletal Product Name: FTX-1821
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: FSHD Society
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 20, 2023
Details:
FTX-6058 is an investigational oral small-molecule inhibitor of embryonic ectoderm development which leads to potent downregulation of key fetal globin repressors, including BCL11A, thereby causing an increase in fetal hemoglobin.
Lead Product(s): FTX-6058
Therapeutic Area: Genetic Disease Product Name: FTX-6058
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2023
Details:
Fulcrum Therapeutics intends to use the net proceeds for the development of FTX-1821 (losmapimod), a small molecule, for the treatment of facioscapulohumeral muscular dystrophy (FSHD).
Lead Product(s): Losmapimod
Therapeutic Area: Musculoskeletal Product Name: FTX-1821
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Goldman Sachs & Co.
Deal Size: $125.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 17, 2023
Details:
Results reported from the ReDUX4 trial demonstrated slowed disease progression and improved function, including positive impacts on upper extremity strength, supporting Losmapimod’s (FTX-1821) potential to be a transformative therapy for the treatment of FSHD.
Lead Product(s): Losmapimod
Therapeutic Area: Musculoskeletal Product Name: FTX-1821
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2022
Details:
Losmapimod is an oral small molecule that selectively inhibit p38α/β mitogen activated protein kinase (MAPK) has the potential to be the first therapy to treat FSHD, the second most common form of muscular dystrophy.
Lead Product(s): Losmapimod
Therapeutic Area: Musculoskeletal Product Name: FTX-1821
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 05, 2022
Details:
Data from first subjects to receive a 6 mg dose of FTX-6058, an oral HbF inducer, showed a rapid and robust induction of HbF, and subjects achieved increases of up to 6.3% over baseline.
Lead Product(s): FTX-6058
Therapeutic Area: Genetic Disease Product Name: FTX-6058
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2022
Details:
FTX-6058 is an investigational oral small-molecule Embryonic Ectoderm Development Inhibitor (EEDI) that has demonstrated robust induction of fetal hemoglobin (HbF) in human cells and animal models of sickle cell disease (SCD).
Lead Product(s): FTX-6058
Therapeutic Area: Genetic Disease Product Name: FTX-6058
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2022
Details:
Losmapimod is an investigational, selective p38α/β mitogen activated protein kinase (MAPK) inhibitor, that demonstrates potential to slow or stop disease progression in facioscapulohumeral muscular dystrophy from its clinical data.
Lead Product(s): Losmapimod
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
